Abstract:Alzheimer's disease (AD) has an insidious onset and lacks clear early diagnostic markers, and by the time overt dementia symptoms appear, the disease is already in the mid-to-late stages. The search for early diagnostic markers of AD may open a critical window for Alzheimer's treatment and facilitate early intervention to slow the progression of AD. In this study, we aimed to explore the imaging markers for early diagnosis of AD through the combined application of structural magnetic resonance imaging (sMRI), resting-state functional magnetic resonance imaging (rs-fMRI), and 1 H-magnetic resonance spectroscopy ( 1 H-MRS) multimodal magnetic resonance imaging (MRI) techniques at the animal experimental level, with the aim to provide a certain reference for early clinical diagnosis of AD. First, sMRI scans were performed on 4-month-old amyloid beta precursor protein/presenilin 1 (APP/PS1) transgenic AD model mice and wild type mice of the same litter using a 7.0 T animal MRI scanner to analyze the differential brain regions with structural changes in the gray matter of the brain by voxel-based morphometry (VBM). Next, rs-fMRI scans were performed to analyze the differential brain regions between groups for local spontaneous brain activity and functional connectivity (FC) between brain regions. Finally, 1 H-MRS scans were performed to quantify and analyze intergroup differences in the relative concentrations of different metabolites within regions of interest (cortex and hippocampus). Compared with wild type mice, the volume of the left hippocampus, and right olfactory bulb of APP/PS1 transgenic AD model mice were reduced, the functional activity of the bilateral hippocampus, right piriform cortex and right caudate putamen was reduced, the functional network connectivity of the hippocampus was impaired, and the relative content of N-acetylaspartate (NAA)in the hippocampus was decreased. In addition, this study found that imaging changes in olfactory-related brain regions were closely associated with AD diagnosis, and these findings may provide some reference for the early diagnosis of AD.

Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer’s disease: a systematic review

Progress on early diagnosing Alzheimer's disease

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

PET and MRI Imaging in Alzheimer’s Disease：Potential Mechanisms and Findings

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease

Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease

Progress of Clinical Laboratory Tests and Molecular Imaging for Diagnosis of Alzheimer's Disease

Integrated Positron Emission Tomography/Magnetic Resonance Imaging in Clinical Diagnosis of Alzheimer’s Disease

Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future

Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging

Research progress in multimodal imaging analysis of Alzheimer's disease

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Biomarkers Associated with the Pathogenesis of Alzheimer’s Disease

Early Diagnosis of Alzheimer’s Disease: Moving Toward a Blood-Based Biomarkers Era

Seeing beyond the symptoms: biomarkers and brain regions linked to cognitive decline in Alzheimer's disease

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Advances in MRI in diagnosis of early-stage Alzheimer’sdisease